EU Clinical Trial 2018-003146-17

A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction  May 21, 2019

Main objective of the trial: Comparison of the effects of twice daily (bis in die [BID]) oral administration of 2 doses of firibastat to those of BID oral administration of ramipril on the change from Baseline in left ventricular ejection fraction (LVEF) assessed by cardiac magnetic resonance imaging (CMRI) on Day 84 Comparacion de los efectos de la administración oral dos veces al día (bis in die [2vd]) de 2 dosis de firibastat con los de la administración oral 2vd de ramipril en el cambio desde el inicio en la fracción de eyección ventricular izquierda (FEVI) evaluada por resonancia magnética cardíaca (RMC) el día 84.

Parties

Sponsors
Countries
BE CZ DE ES FR GB HU IT NL PL SK US
Keywords
Firibastat QGC001 RAMIPRIL Triatec®

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.